CTOs on the Move


 
Biocon Limited, publicly listed in 2004, is India`s largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.biocon.com
  • 485 Hwy 1 (S) Suite B 305
    Iselin, NJ USA 08830
  • Phone: 732.636.2950

Executives

Name Title Contact Details

Similar Companies

Insite Vision

Insite Vision is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeras Global TB Vaccine Foundation

Aeras is constantly producing new constructs that will also be made available following phenotypic, genotypic and stability characterization. Aeras is also glad to provide shigella carrier strains with capsids expressing TB antigens under similar

Corium

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world`s largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

Accugenix

Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing

Argentis Pharmaceuticals

arGentis™ Pharmaceuticals, LLC is a private TN based pharmaceutical company with a mid-stage Orphan Drug treatment (ARG201) for late stage diffuse systemic scleroderma (dcSSc). The company is seeking capital or a partner to complete a Pivotal Clinical Trial which will enable obtaining marketing approval in the EU. The Company has a genotype marker (ROT1) that predicts patient response to treatment by oral tolerance for treatments like ARG201 for dcSSc. Furthermore, arGentis™ has a treatment for Rheumatoid arthritis (ARG301) that is in a Phase I Clinical Trial in the US.